Star Combo Pharma Ltd (S66) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Star Combo Pharma Ltd (S66) has a cash flow conversion efficiency ratio of 0.015x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$575.23K ≈ $407.01K USD) by net assets (AU$38.68 Million ≈ $27.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See S66 net asset quality score to measure how much of total assets are equity-financed.
Star Combo Pharma Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Star Combo Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check S66 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Star Combo Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Star Combo Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suryalakshmi Cotton Mills Limited
NSE:SURYALAXMI
|
0.071x |
|
RE Royalties Ltd
V:RE
|
0.166x |
|
Nidaros Sparebank
OL:NISB
|
N/A |
|
Agripower France Sa
PA:ALAGP
|
-0.394x |
|
Welcron Hantec Co.Ltd
KQ:076080
|
-1.076x |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
-0.094x |
|
Medicon Hellas S.A.
AT:MEDIC
|
0.008x |
|
TR Property Investment Trust plc
LSE:TRY
|
0.028x |
Annual Cash Flow Conversion Efficiency for Star Combo Pharma Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Star Combo Pharma Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see S66 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$38.26 Million ≈ $27.07 Million |
AU$11.94 Million ≈ $8.45 Million |
0.312x | +3404.96% |
| 2024-06-30 | AU$33.51 Million ≈ $23.71 Million |
AU$-316.45K ≈ $-223.91K |
-0.009x | -116.74% |
| 2023-06-30 | AU$33.26 Million ≈ $23.53 Million |
AU$1.88 Million ≈ $1.33 Million |
0.056x | +2193.37% |
| 2022-06-30 | AU$35.41 Million ≈ $25.05 Million |
AU$87.11K ≈ $61.64K |
0.002x | -73.14% |
| 2021-06-30 | AU$36.19 Million ≈ $25.61 Million |
AU$331.53K ≈ $234.58K |
0.009x | +140.03% |
| 2020-06-30 | AU$44.50 Million ≈ $31.49 Million |
AU$-1.02 Million ≈ $-720.42K |
-0.023x | +79.06% |
| 2019-06-30 | AU$20.00 Million ≈ $14.15 Million |
AU$-2.19 Million ≈ $-1.55 Million |
-0.109x | +3.35% |
| 2018-06-30 | AU$16.26 Million ≈ $11.50 Million |
AU$-1.84 Million ≈ $-1.30 Million |
-0.113x | -290.16% |
| 2017-06-30 | AU$15.68 Million ≈ $11.10 Million |
AU$932.20K ≈ $659.59K |
0.059x | -82.19% |
| 2016-06-30 | AU$3.88 Million ≈ $2.75 Million |
AU$1.30 Million ≈ $917.50K |
0.334x | -- |
About Star Combo Pharma Ltd
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its pro… Read more